Product Information
VRAYLAR 4.5 MG CAPSULE is a brand product labeled by Allergan, Inc., priced at $50.8012 per EA under NDC 61874014530. Its NADAC has been published 514 times since Oct 19, 2016.
FDA first approved this application on Sep 17, 2015.
Strength
4.5 mg/1
Manufacturer
Allergan, Inc.NDC
61874014530
Classification
Brand
Dosage Form
CAPSULE, GELATIN COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
CARIPRAZINEApproval Type
New Drug (NDA)
FDA Application
NDA204370FDA Approved
9/17/2015
On Market Since
9/17/2015
Pharmacological Classes
Price Statistics
The NADAC for VRAYLAR 4.5 MG CAPSULE has been published 514 times since Oct 19, 2016, and over the history we have for it it has risen 58.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $50.8012 per EA |
|---|---|
| All-time high | $50.9395 (May 13, 2026) |
| All-time low | $32.0189 (Oct 19, 2016) |
| 52-week high | $50.9395 |
| 52-week low | $48.4901 |
| Median price | $40.4960 |
| Average price | $41.6382 |
| Largest weekly change | +9.5% (Jan 10, 2018) |
| Weeks tracked | 514 |
| Tracking since | Oct 19, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the cariprazine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of VRAYLAR 4.5 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for VRAYLAR 4.5 MG CAPSULE, manufactured by Allergan, Inc., is $50.8012 per EA (NDC 61874014530), effective Aug 19, 2026.
How has the price of VRAYLAR 4.5 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for VRAYLAR 4.5 MG CAPSULE has risen 58.7%. It has been tracked across 514 weekly CMS publications since Oct 19, 2016.
What are the highest and lowest recorded NADAC prices for VRAYLAR 4.5 MG CAPSULE?
Since Oct 19, 2016, the NADAC for VRAYLAR 4.5 MG CAPSULE has ranged from a low of $32.0189 (Oct 19, 2016) to a high of $50.9395 (May 13, 2026), with a median of $40.4960 per EA.
Are there cheaper alternatives to VRAYLAR 4.5 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of VRAYLAR 4.5 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures VRAYLAR 4.5 MG CAPSULE?
VRAYLAR 4.5 MG CAPSULE (NDC 61874014530) is labeled by Allergan, Inc., and CMS classifies it as a brand product.